Visible Alpha

In today's fast-paced and often volatile financial markets, selecting the most impactful investment opportunities is more important than ever. Private equity fund managers and investment bankers require streamlined processes that enable more informed decision-making. In this joint webinar with S&P Global Market Intelligence, join our experts as they discuss how you can leverage S&P Global and Visible Alpha's combined data solution to conduct market research, hone in on attractive investment opportunities, perform peer comparisons, and gauge a target or sector’s future performance. Register now: https://okt.to/JeE36A

With the 𝗡𝗔𝗩 𝗙𝗲𝗮𝘁𝘂𝗿𝗲 𝗳𝗼𝗿 𝗩𝗶𝘀𝗶𝗯𝗹𝗲 𝗔𝗹𝗽𝗵𝗮 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀, you can unlock more efficient and streamlined analysis of the mining industry with detailed net asset value (NAV) data. Core Capabilities of the NAV Feature: 💵Empowers you to 𝗲𝗮𝘀𝗶𝗹𝘆 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗼𝗳 𝗮 𝗰𝗼𝗺𝗽𝗮𝗻𝘆’𝘀 𝗺𝗶𝗻𝗶𝗻𝗴 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀, down to the level of individual mining assets and non-mining adjustments, providing you with unparalleled granular insights. 🖥️𝗦𝘂𝗽𝗽𝗹𝗶𝗲𝘀 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗮𝗻𝗱 𝘂𝗽-𝘁𝗼-𝗱𝗮𝘁𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 on a company’s owned mines, their gross asset values, and individual NAVs, at either the consensus level or (with entitlements) across brokers. ⚖️Enables you to 𝗾𝘂𝗶𝗰𝗸𝗹𝘆 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 𝗡𝗔𝗩 𝗱𝗮𝘁𝗮 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝗶𝗻𝗶𝗻𝗴 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗽𝗲𝗲𝗿𝘀–all within a single platform–facilitating deeper competitive intelligence. 🎚️Allows you to 𝗽𝗲𝗿𝗳𝗼𝗿𝗺 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗡𝗔𝗩 𝗮𝗻𝗮𝗹𝘆𝘀𝗲𝘀, with options for custom consensus, currency conversion, and NAV revisions. Ready to try out the NAV Feature for yourself? Request a demo today: https://okt.to/qRev4Z

Leverage the power of Visible Alpha Insights directly within Excel using our powerful 𝗘𝘅𝗰𝗲𝗹 𝗔𝗱𝗱-𝗜𝗻. With the Excel Add-In, you can: 📈Embed real-time consensus data directly into your company models 🔎Audit data with full sourcing transparency and calculation logic ⚠️Easily identify outlier calls in broker estimates ⏰View revisions over time In addition, tear sheets are available to aid you in pre- and post-earnings analysis. Want to learn more about the Excel Add-In? Visit: https://okt.to/8RBxEG

Earnings season is more than a quarterly task—it's a unique opportunity to showcase your company’s story on a global stage. With increasing stock coverage and macroeconomic headlines competing for attention, standing out has never been more critical. Explore our IR Playbook to master communications throughout the earnings cycle and make a lasting impact https://okt.to/4UxVD6

Ready to stay ahead of airline industry trends? Our latest Airline KPI Guide is here to help you navigate the future of aviation with confidence. Explore key market expectations with granular insights on capacity metrics, utilization rates, and more. Get the tools you need to anticipate shifts and make informed predictions about airline performance. https://okt.to/2I6CAk

Last year the FDA approved 55 novel drugs for commercial use, with several hundred entering clinical trial phase 1. For pharmaceutical analysts, staying ahead of the curve is essential. How do you keep up with the rapid pace of innovation? One solution: BioPharma's Drug Screener. Request a demo: https://okt.to/C7UvDB

From benchmarking and back testing to signal generation and comparative analysis, Visible Alpha Insights empowers researchers and analysts with the tools they need to make informed decisions. Discover more: https://okt.to/OsZ6FJ

With AI-exposed revenues expected to rise to nearly $780 billion by the end of 2025, our AI Monitor is a must-have resource for investment professionals looking to uncover growth opportunities and identify emerging leaders in the fast-evolving AI landscape. Stay ahead of the competition and discover how our AI Monitor can enhance your investment strategies! Read the full press release for more details: https://okt.to/dnx5B9

When the market takes unexpected turns, having access to comprehensive and insightful data can make all the difference. With Visible Alpha, you gain granular insights, equipping you to see what others can't. Learn more: https://okt.to/M7sPgu

The pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. The industry grapples with rapid, complex drug launches, increased competition, and delayed ROI, with about half of the leading companies missing their earnings guidance this year. These challenges highlight the need for precise financial forecasting, strategic data-driven decisions, and a comprehensive understanding of market views on individual drugs. Our latest eBook, 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀, offers actionable insights on how you can Identify new opportunities, evaluate market competitiveness, gauge market expectations, analyze historical data, access forward-looking estimates, and conduct rapid financial analysis at the drug level. Want to learn more about how you can evolve your biopharma financial analysis? Download our eBook today: https://okt.to/EN32iv